127 related articles for article (PubMed ID: 19675744)
1. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
Kraemer A; Hauser S; Kim Y; Gorschlüter M; Müller SC; Brossart P; Schmidt-Wolf IG
Ger Med Sci; 2009 Jun; 7():Doc04. PubMed ID: 19675744
[TBL] [Abstract][Full Text] [Related]
2. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
3. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
4. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
Amato RJ; Rawat A
Invest New Drugs; 2006 May; 24(3):171-5. PubMed ID: 16086096
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
Amato RJ; Mohammad T
J Exp Ther Oncol; 2008; 7(1):41-7. PubMed ID: 18472641
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
7. Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
Tsimafeyeu I; Demidov L; Kharkevich G; Petenko N; Galchenko V; Sinelnikov I; Naidzionak U
Am J Clin Oncol; 2012 Jun; 35(3):251-4. PubMed ID: 21358295
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Walter B; Schrettenbrunner I; Vogelhuber M; Grassinger J; Bross K; Wilke J; Suedhoff T; Berand A; Wieland WF; Rogenhofer S; Andreesen R; Reichle A
Med Oncol; 2012 Jun; 29(2):799-805. PubMed ID: 21607771
[TBL] [Abstract][Full Text] [Related]
10. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide therapy for renal cell carcinoma.
Amato RJ
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S59-65. PubMed ID: 12850528
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
14. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Laber DA; Khan MI; Kloecker GH; Schonard C; Taft BS; Salvador C
Cancer Biol Ther; 2007 Jun; 6(6):840-5. PubMed ID: 17582215
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of thalidomide in renal-cell carcinoma.
Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A
Ann Oncol; 2002 Jul; 13(7):1029-35. PubMed ID: 12176780
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]